Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KMO | O15229 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | MEP1B | Q16820 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | UNG | P13051 | 1/20 | 0.46 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31736878 | 1.00 | CA12 (0.50) | CA12CA1CA2CA6CA9 | |
| SCHEMBL20471083 | 0.82 | TSHR (0.58) | CA12CA1CA2CA6CA9 | |
| Isophthalic Acid SCHEMBL22462 | 0.80 | CA12 (0.71) | CA12CA1CA2CA6CA9 | |
| Isophthalic Acid SCHEMBL28462260 | 0.80 | CA12 (0.71) | CA12CA1CA2CA6CA9 | |
| Isophthalic Acid SCHEMBL20500514 | 0.80 | CA12 (0.71) | CA12CA1CA2CA6CA9 | |
| Isophthalic Acid SCHEMBL147366 | 0.80 | CA12 (0.71) | CA12CA1CA2CA6CA9 | |
| Isophthalic Acid SCHEMBL2512374 | 0.80 | CA12 (0.71) | CA12CA1CA2CA6CA9 | |
| Isophthalic Acid SCHEMBL28756611 | 0.80 | CA12 (0.71) | CA12CA1CA2CA6CA9 | |
| SCHEMBL60081 | 0.79 | TSHR (0.52) | CA12CA1CA2CA9L3MBTL1 | |
| SCHEMBL11791474 | 0.79 | HDAC8 (0.68) | CA12CA1CA2CA6CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025243250-A1 | A PROCESS FOR THE PREPARATION OF 3-[5-(2-FLUOROPHENYL)-1,2,4-OXADIAZOL-3-YL]BENZOIC ACID | BIOPHORE INDIA PHARMACEUTICALS PVT. LTD. (IN) | 2025-11-27 | — | — | WO | disclosed |
| US-20240246956-A1 | CLASS IIA HISTONE DEACETYLASE (HDAC) DEGRADER LIGANDS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-25 | — | — | US | disclosed |
| EP-4333842-A1 | CLASS IIA HISTONE DEACETYLASE (HDAC) DEGRADER LIGANDS AND METHODS OF USE THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-3704113-B1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-11 | — | — | EP | disclosed |
| US-20230265082-A1 | SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265082-A1 | SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-08-24 | — | — | US | disclosed |
| WO-2022235565-A1 | CLASS IIA HISTONE DEACETYLASE (HDAC) DEGRADER LIGANDS AND METHODS OF USE THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
| WO-2022035805-A1 | SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
| EP-3704113-A1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2020-09-09 | — | — | EP | disclosed |
| US-20200268720-A1 | METHODS OF USE OF A CLASS IIA HDAC INHIBITOR | GLAXOSMITHKLINE LLC | 2020-08-27 | — | — | US | disclosed |
| EP-2310013-A1 | BICYCLIC TRIAZOLE DERIVATIVES FOR TREATING TUMORS | Merck Patent GmbH (DE) | 2011-04-20 | — | — | EP | disclosed |
| US-20100280030-A1 | 2-OXO-3-BENZYLBENZOXAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS MET KINASE INHIBITORS FOR THE TREATMENT OF TUMOURS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-11-04 | — | — | US | disclosed |
| US-20100273796-A1 | 2-BENZYLPYRIDAZINONE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-10-28 | — | — | US | disclosed |
| US-20100234354-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | disclosed |
| WO-2010078905-A1 | BENZOTHIAZOLONE DERIVATIVE | MERCK PATENT GMBH (DE) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010017870-A1 | BICYCLIC TRIAZOLE DERIVATIVES FOR TREATING TUMORS | MERCK PATENT GMBH (DE) | 2010-02-18 | — | — | WO | disclosed |
| EP-2150551-A1 | 2-OXO-3-BENZYL-BENZOXAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS MET KINASE INHIBITORS FOR THE TREATMENT OF TUMORS | Merck Patent GmbH (DE) | 2010-02-10 | — | — | EP | disclosed |
| US-20090181964-A1 | Propane-1,3-Dione Derivative or Salt Thereof | ASTELLAS PHARMA INC. | 2009-07-16 | — | — | US | disclosed |
| WO-2008148449-A1 | 2-OXO-3-BENZYL-BENZOXAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS MET KINASE INHIBITORS FOR THE TREATMENT OF TUMORS | MERCK PATENT GMBH (DE) | 2008-12-11 | — | — | WO | disclosed |
| EP-1864976-A1 | PROPANE-1,3-DION DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273796-A1 | 2-BENZYLPYRIDAZINONE DERIVATIVES AS MET KINASE INHIBITORS | ERBB2, RET, MET | CA12 4182/4885CA1 4265/4885CA2 2244/4885 |
| US-20100280030-A1 | 2-OXO-3-BENZYLBENZOXAZOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS MET KINASE INHIBITORS FOR THE TREATMENT OF TUMOURS | ERBB2, RET, MET | CA12 2790/4885CA1 3780/4885CA2 1570/4885 |
| US-20090181964-A1 | Propane-1,3-Dione Derivative or Salt Thereof | GNRHR, KISS1R, FSHR | CA12 2124/4885CA1 1627/4885CA2 289/4885 |
| US-20230265082-A1 | SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | USP28, USP1, USP18 | CA12 1881/4885CA1 1677/4885CA2 3537/4885 |
| US-20200268720-A1 | METHODS OF USE OF A CLASS IIA HDAC INHIBITOR | HDAC7, HDAC8, HDAC5 | CA12 933/4885CA1 807/4885CA2 1041/4885 |
| US-20240246956-A1 | CLASS IIA HISTONE DEACETYLASE (HDAC) DEGRADER LIGANDS AND METHODS OF USE THEREOF | HDAC4, HDAC1, HDAC7 | CA12 1489/4885CA1 1303/4885CA2 2244/4885 |
| US-20100234354-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | CA12 4693/4885CA1 4660/4885CA2 3695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.